Literature DB >> 16506439

Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics.

Carlo Caltagirone1, Angelo Bianchetti, Monica Di Luca, Patrizia Mecocci, Alessandro Padovani, Elvezio Pirfo, Pierluigi Scapicchio, Umberto Senin, Marco Trabucchi, Massimo Musicco.   

Abstract

A committee of experts from the Italian Association of Psychogeriatrics compiled the following report, which was then approved by a Steering Committee (comprising 20 specialists in neurology, psychiatry or geriatrics) from the Association and by two Alzheimer associations representing patients and families: the Italian Association for Alzheimer's Disease and the Italian Federation for Alzheimer's Disease. The report is based on a comprehensive review of the scientific literature on the treatment of Alzheimer's disease, discusses methodological aspects of dementia management, and details the limitations of current therapies. These guidelines are, in general, consistent with the principles of evidence-based medicine; however, for some controversial or poorly investigated issues, the guidelines integrate scientific evidence with experience and opinions from experts working in the clinical setting. In particular, the clinical experience of experts has been used to define recommendations for starting and interrupting pharmacotherapy, and to critically review evidence about the efficacy of non-pharmacological interventions. The principal pharmacotherapeutic interventions covered in the guidelines are acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and memantine. The main non-pharmacological interventions reviewed are memory training, reality orientation therapy, and combined non-pharmacological interventions. Other issues covered are opportunities for Alzheimer's disease prevention, various modalities of care, and the treatment of comorbidities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16506439     DOI: 10.2165/00002512-200522001-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  254 in total

1.  Placebo-controlled study of divalproex sodium for agitation in dementia.

Authors:  A P Porsteinsson; P N Tariot; R Erb; C Cox; E Smith; L Jakimovich; J Noviasky; N Kowalski; C J Holt; C Irvine
Journal:  Am J Geriatr Psychiatry       Date:  2001       Impact factor: 4.105

2.  Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients--evidence from the Systolic Hypertension in Europe Trial.

Authors:  J A Staessen; L Thijs; H Celis; J Gasowski; J G Wang; R H Fagard
Journal:  S Afr Med J       Date:  2001-12

3.  Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation.

Authors:  W D Heiss; J Kessler; R Mielke; B Szelies; K Herholz
Journal:  Dementia       Date:  1994 Mar-Apr

4.  Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease.

Authors:  A Marriott; C Donaldson; N Tarrier; A Burns
Journal:  Br J Psychiatry       Date:  2000-06       Impact factor: 9.319

5.  Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change.

Authors:  Martha Clare Morris; Denis A Evans; Christine C Tangney; Julia L Bienias; Robert S Wilson; Neelum T Aggarwal; Paul A Scherr
Journal:  Am J Clin Nutr       Date:  2005-02       Impact factor: 7.045

6.  Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH Initiative.

Authors:  Laura N Gitlin; Laraine Winter; Mary Corcoran; Marie P Dennis; Sandy Schinfeld; Walter W Hauck
Journal:  Gerontologist       Date:  2003-08

7.  Reducing anxiety in Alzheimer's disease family caregivers: the effectiveness of a nine-week cognitive-behavioral intervention.

Authors:  Rhonda L Akkerman; Sharon K Ostwald
Journal:  Am J Alzheimers Dis Other Demen       Date:  2004 Mar-Apr       Impact factor: 2.035

8.  Dawn-dusk simulation light therapy of disturbed circadian rest-activity cycles in demented elderly.

Authors:  Paola Fontana Gasio; Kurt Kräuchi; Christian Cajochen; Eus van Someren; Isabelle Amrhein; Mona Pache; Egemen Savaskan; Anna Wirz-Justice
Journal:  Exp Gerontol       Date:  2003 Jan-Feb       Impact factor: 4.032

Review 9.  An active and socially integrated lifestyle in late life might protect against dementia.

Authors:  Laura Fratiglioni; Stephanie Paillard-Borg; Bengt Winblad
Journal:  Lancet Neurol       Date:  2004-06       Impact factor: 44.182

10.  Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis.

Authors:  Martha Sajatovic; Jamie A Mullen; Dennis E Sweitzer
Journal:  J Clin Psychiatry       Date:  2002-12       Impact factor: 4.384

View more
  11 in total

Review 1.  Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?

Authors:  Ben Seltzer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

2.  A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.

Authors:  Brenna N Renn; Ali Abbas Asghar-Ali; Stephen Thielke; Angela Catic; Sharyl R Martini; Brian G Mitchell; Mark E Kunik
Journal:  Am J Geriatr Psychiatry       Date:  2017-10-10       Impact factor: 4.105

3.  Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.

Authors:  Alberto Pilotto; M Franceschi; G D'Onofrio; A Bizzarro; F Mangialasche; L Cascavilla; F Paris; M G Matera; Andrea Pilotto; A Daniele; P Mecocci; C Masullo; B Dallapiccola; D Seripa
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

4.  Consensus statement on dementia education and training in Europe.

Authors:  M Tsolaki; V Papaliagkas; G Anogianakis; R Bernabei; M Emre; L Frolich; P J Visser; J P Michel; T Pirttila; M Olde Rikkert; H Soininen; T Sobow; B Vellas; F Verhey; B Winblad
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

5.  Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice.

Authors:  Julia Haberstroh; Harald Hampel; Johannes Pantel
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

6.  Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment?

Authors:  Katie Palmer; Massimo Musicco; Carlo Caltagirone
Journal:  Int J Alzheimers Dis       Date:  2010-08-17

7.  Ethical questions in the treatment of subjects with dementia. Part I. Respecting autonomy: awareness, competence and behavioural disorders.

Authors:  C A Defanti; A Tiezzi; M Gasparini; M Gasperini; M Congedo; P Tiraboschi; D Tarquini; E Pucci; C Porteri; V Bonito; L Sacco; S Stefanini; L Borghi; L Colombi; N Marcello; O Zanetti; R Causarano; A Primavera
Journal:  Neurol Sci       Date:  2007-08       Impact factor: 3.307

8.  Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.

Authors:  David S Geldmacher
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

9.  The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.

Authors:  Haris Carageorgiou; Antonios C Sideris; Ioanna Messari; Chrissoula I Liakou; Stylianos Tsakiris
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

10.  Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.

Authors:  Roberta Annicchiarico; Alessia Federici; Carla Pettenati; Carlo Caltagirone
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.